Details of Disease

General Information of Disease (ID: DIS8TYKO)

Disease Name Gastrin-producing neuroendocrine tumor
Synonyms
malignant gastrinoma; gastrinoma; gastrin-producing neuroendocrine tumor; gastrin-producing NET; gastrin secreting tumour; gastrin secreting tumor; gastrin cell tumour; gastrin cell tumor; G-cell tumour; G-cell tumor; G-cell gastrin producing tumour; G-cell gastrin producing tumor; G cell tumour; G cell tumor
Definition A gastrin-producing neuroendocrine tumor. It is usually located in the pancreas but it is also found at other anatomic sites, including the stomach and small intestine.
Disease Hierarchy
DISDR98B: Digestive system neuroendocrine tumor, grade 1/2
DIS8TYKO: Gastrin-producing neuroendocrine tumor
Disease Identifiers
MONDO ID
MONDO_0003523
MESH ID
D015408
UMLS CUI
C0017150
MedGen ID
6551
SNOMED CT ID
16189002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Romidepsin DMT5GNL Approved Small molecular drug [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 6 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FFAR1 TTB8FUC Strong Altered Expression [2]
GRPR TTC1MVT Strong Biomarker [3]
HRH2 TTQHJ1K Strong Biomarker [4]
PYGM TTZHY6R Strong Genetic Variation [5]
SCT TTOBVIN Strong Biomarker [6]
SSTR5 TT2BC4G Strong Altered Expression [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTT(s)
This Disease Is Related to 6 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BBS2 OTPF9JIB Strong Biomarker [8]
CHGA OTXYX5JH Strong Biomarker [9]
GRP OT8JDFNI Strong Biomarker [8]
NMB OT4NLN6H Strong Biomarker [8]
NMBR OTBJEGPN Strong Biomarker [8]
POTEF OTV3WXYE Definitive Biomarker [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 Romidepsin FDA Label
2 GPR40 gene expression in human pancreas and insulinoma.Biochem Biophys Res Commun. 2005 Dec 30;338(4):1788-90. doi: 10.1016/j.bbrc.2005.10.161. Epub 2005 Nov 2.
3 Design, synthesis and invitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC(1)-Receptors concomitantly overexpressed on various malignancies - Is the concept feasible?.Eur J Med Chem. 2018 Jul 15;155:84-95. doi: 10.1016/j.ejmech.2018.05.047. Epub 2018 May 29.
4 Management of the hormonal syndrome of neuroendocrine tumors.Arch Med Sci. 2017 Apr 1;13(3):515-524. doi: 10.5114/aoms.2016.60311. Epub 2016 Jun 1.
5 Pancreatic endocrine tumors with loss of heterozygosity at the multiple endocrine neoplasia type I locus.Am J Surg. 1997 Jun;173(6):518-20. doi: 10.1016/s0002-9610(97)00001-9.
6 Biochemical Testing in Patients with Neuroendocrine Tumors.Front Horm Res. 2015;44:24-39. doi: 10.1159/000381981. Epub 2015 Aug 14.
7 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.Virchows Arch. 2002 May;440(5):461-75. doi: 10.1007/s00428-002-0609-x. Epub 2002 Mar 23.
8 Mechanisms of bombesin on growth of gastrinoma (PT) in vivo.Dig Dis Sci. 1996 Nov;41(11):2180-6. doi: 10.1007/BF02071398.
9 Chromogranin A in gastrinomas: Promises and pitfalls.Clin Chim Acta. 2015 Jun 15;446:15-20. doi: 10.1016/j.cca.2015.03.039. Epub 2015 Apr 8.
10 Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.J Clin Endocrinol Metab. 2007 Nov;92(11):4394-402. doi: 10.1210/jc.2007-0986. Epub 2007 Aug 21.